Celldex Therapeutics, Inc. CLDX

Healthcare SIC 2835 - In Vitro & In Vivo Diagnostic Substances NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Celldex Therapeutics, Inc., which we refer to as "Celldex," "we," "us," "our" or the "Company," is a biopharmaceutical company dedicated to exploring the science of mast cell biology and developing therapeutic antibodies which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Our drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.

We are focusing our efforts and resources on the continued research and development of

● Barzolvolimab (also referred to as CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is currently being studied across multiple mast cell driven diseases including

Last close 29.25 2026-10-23
Market cap $2.30B 2026-06-30 share count
52-week range 22.10 - 45.14

Valuation FY2025 figures against the last close

P/S1,486.7x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-3.90

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $1.5M$7.0M$6.9M$2.4M$4.7M$7.4M$3.6M$9.5M$12.7M$6.8M
Cost of revenue $200.0K$200.0K$300.0K$100.0K$100.0K$200.0K$100.0K$700.0K$700.0K$1.6M
Gross profit $1.3M$6.8M$6.6M$2.3M$4.6M$7.2M$3.5M$8.8M$12.0M$5.2M
R&D $245.1M$163.6M$118.0M$82.3M$53.3M$42.5M$42.7M$66.4M$96.2M$102.7M
SG&A $43.8M$38.5M$30.9M$27.2M$20.5M$14.5M$15.4M$19.3M$25.0M$36.0M
Total operating expenses $288.9M$202.1M$161.4M$117.6M$75.9M$70.8M$58.6M$166.0M$134.3M$139.7M
Operating income -$287.4M-$195.1M-$154.5M-$115.2M-$71.2M-$63.4M-$55.0M-$156.4M-$121.5M-$132.9M
Pre-tax income -$258.8M-$157.9M-$141.4M-$112.3M-$70.7M-$60.9M-$50.9M-$151.9M-$117.3M-$128.5M
Income tax $0$0$0—$227.0K$1.2M—$765.0K$24.3M—
Net income -$258.8M-$157.9M-$141.4M-$112.3M-$70.5M—————
EPS, basic -3.90-2.45-2.92-2.40-1.64-2.02-3.51———
EPS, diluted -3.90-2.45-2.92-2.40-1.64-2.02-3.51-14.48-10.86-18.99
Shares, diluted (wtd. avg.) 66.4M64.4M48.4M46,88842,87029,64014,507———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $28.9M$28.4M$34.8M$29.4M$39.1M$43.8M$11.2M$24.3M$40.3M$42.5M
Short-term investments $489.7M$696.9M$388.8M$275.5M$369.1M$150.6M$53.2M$69.7M$99.1M$147.3M
Total current assets $534.7M$747.2M$431.7M$317.7M$410.8M$197.8M$66.7M$99.1M$144.8M$195.6M
Property, plant and equipment $5.3M$4.3M$4.1M$3.7M$3.6M$3.8M$4.0M$6.1M$10.4M$13.2M
Goodwill ————————$91.0M$91.0M
Other intangibles $27.2M$27.2M$27.2M$27.2M$27.2M$30.7M$48.7M$48.7M$67.6M$81.5M
Total assets $583.0M$792.3M$465.6M$352.7M$444.7M$235.8M$122.9M$155.8M$315.6M$383.4M
Accounts payable $1.2M$3.3M$3.5M$3.3M$1.2M$1.0M$1.2M$1.1M$1.7M$1.7M
Total current liabilities $51.0M$39.5M$31.1M$18.6M$16.5M$14.2M$11.6M$12.6M$27.7M$35.2M
Total liabilities $55.8M$45.3M$36.5M$26.5M$25.2M$26.5M$28.9M$31.7M$79.3M$117.9M
Retained earnings -$1.81B-$1.56B-$1.40B-$1.26B-$1.14B-$1.07B-$1.01B-$962.4M-$812.5M-$719.5M
Total equity $527.2M$747.0M$429.2M$326.2M$419.5M$209.4M$94.0M$124.1M$236.4M$265.4M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$210.9M-$157.8M-$107.3M-$103.7M-$60.9M-$40.4M-$46.4M-$75.2M-$99.9M-$113.0M
Depreciation and amortisation $3.4M$3.2M$3.0M$2.9M$3.1M$3.9M$4.9M$3.6M$4.4M$3.1M
Stock-based compensation $36.2M$34.2M$23.9M$15.6M$9.0M$3.9M$4.6M$8.1M$12.3M$15.3M
Capital expenditure $2.7M$1.9M$1.8M$1.8M$1.2M$1.6M$731.0K$813.0K$1.8M$2.8M
Investing cash flow $209.1M-$290.1M-$105.8M$89.9M-$216.2M-$98.2M$17.1M$29.8M$46.5M$68.9M
Financing cash flow $2.4M$441.4M$218.5M$4.1M$272.4M$171.2M$16.3M$29.4M$51.3M$14.5M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-050884.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -300M -200M -100M 0 100M Revenue, FY2016: 6.8M Gross profit, FY2016: 5.2M Revenue, FY2017: 12.7M Gross profit, FY2017: 12M Revenue, FY2018: 9.5M Gross profit, FY2018: 8.8M Revenue, FY2019: 3.6M Gross profit, FY2019: 3.5M Revenue, FY2020: 7.4M Gross profit, FY2020: 7.2M Revenue, FY2021: 4.7M Gross profit, FY2021: 4.6M Net income, FY2021: -70.5M Revenue, FY2022: 2.4M Gross profit, FY2022: 2.3M Net income, FY2022: -112.3M Revenue, FY2023: 6.9M Gross profit, FY2023: 6.6M Net income, FY2023: -141.4M Revenue, FY2024: 7M Gross profit, FY2024: 6.8M Net income, FY2024: -157.9M Revenue, FY2025: 1.5M Gross profit, FY2025: 1.3M Net income, FY2025: -258.8M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $6.8M $12.7M $9.5M $3.6M $7.4M $4.7M $2.4M $6.9M $7.0M $1.5M
Gross profit $5.2M $12.0M $8.8M $3.5M $7.2M $4.6M $2.3M $6.6M $6.8M $1.3M
Net income — — — — — -$70.5M -$112.3M -$141.4M -$157.9M -$258.8M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Officer or director change Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Other event Item 8.01
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2835

TickerCompanyMarket capP/ERevenue growth
IDXX IDEXX LABORATORIES INC /DE $44.15B 42.8x 10.4%
LNTH Lantheus Holdings, Inc. $6.51B 29.3x 0.5%
NEOG NEOGEN CORP $2.66B — -2.7%
NTLA Intellia Therapeutics, Inc. $1.57B — 16.9%
QDEL QuidelOrtho Corp $941.5M — -1.9%
ACHV ACHIEVE LIFE SCIENCES, INC. $667.8M — —
MYGN MYRIAD GENETICS INC $556.7M — -1.6%
TKNO Alpha Teknova, Inc. $344.7M — 7.4%